447 related articles for article (PubMed ID: 26320385)
1. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
Tauber G; Pavlovsky L; Fenig E; Hodak E
J Am Acad Dermatol; 2015 Nov; 73(5):799-801. PubMed ID: 26320385
[TBL] [Abstract][Full Text] [Related]
2. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
5. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
9. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
12. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib in the treatment of advanced BCC.
O'Kane GM; Lyons T; McDonald I; Mulligan N; Moloney FJ; Murray D; Kelly CM
Ir Med J; 2014; 107(7):215-6. PubMed ID: 25226719
[TBL] [Abstract][Full Text] [Related]
14. Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.
Prescrire Int; 2015 Jan; 24(156):11-4. PubMed ID: 25729822
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
17. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
Lyons TG; O'Kane GM; Kelly CM
Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
Juhasz ML; Marmur ES
J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
[TBL] [Abstract][Full Text] [Related]
20. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]